SAI MedPartners
SAI MedPartners is a global life sciences strategy consultancy serving pharmaceutical, biotechnology, and medical device companies with competitive intelligence, market research, forecasting, market access, and path-to-market positioning services across eight offices in the U.S., Europe, and Asia.
- Company typePrivate
- Founded2011
- HeadquartersReading, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What SAI MedPartners does
SAI MedPartners is a global life sciences strategy consultancy that serves pharmaceutical, biotechnology, and medical device companies. The firm provides integrated services across four pillars: competitive intelligence and benchmarking, market research and forecasting, market access and pricing, and path-to-market positioning. With 250+ employees across eight offices in Reading (HQ), Waltham, London, Zurich, Beijing, Shanghai, and Bangalore, SAI supports hundreds of enterprise healthcare clients across the product lifecycle — from preclinical development through loss of exclusivity. According to company claims, SAI provided strategic support to 31% of new molecular entities launched since 2021. The firm operates through direct, senior-level enterprise consulting engagements with multi-year contracts and quote-based pricing.
The company's offerings span human-delivered consulting, syndicated subscription products, and proprietary technology. Core acquired brands include Fulcrum Research Group (custom quantitative and qualitative market research), PharmaForce International (syndicated benchmarking reports updated annually across oncology, immunology, cardiovascular, CNS, and ophthalmology, with a 20+ year track record), IDEA Pharma (path-to-market strategy using the FIVE-X framework), and The Dunn Group (competitive intelligence). Technology-enabled products include IntelliTraQ (knowledge management), Deployment Analyzer (global sales force deployment data, updated semi-annually), and Synthetic Users — an AI platform generating synthetic healthcare stakeholders (physicians, patients, caregivers) that participate in dynamic interview-based research, with the company claiming up to 93% parity to human respondents. The Synthetic Users platform operates within a SOC 2 Type 2-compliant closed environment.
SAI MedPartners is privately held, backed by Northlane Capital Partners since June 2022. The PE investment funded a roll-up strategy with acquisitions of Fulcrum Research Group (January 2023), PharmaForce International (March 2023), IDEA Pharma (November 2024), and The Dunn Group (December 2025), expanding capabilities and brand portfolio. Founder Erik Nordhoy remains CEO; the leadership team includes BU Presidents for CI/Benchmarking, Strategic Consulting/Analytics (two BU presidents covering Fulcrum and IDEA), Asia (Celia Deng), a CFO (Anders Eriksson), a Chief Medical & Innovation Officer (Alexander Gray), and an EVP of Corporate Development (John Barry). Revenue is not publicly disclosed.
SAI MedPartners firmographics
Firmographics- Name
- SAI MedPartners
- Legal name
- SAI MedPartners LLC
- Website
- https://sai-med.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- SAI MedPartners is a global life sciences strategy consultancy serving pharmaceutical, biotechnology, and medical device companies with competitive intelligence, market research, forecasting, market access, and path-to-market positioning services across eight offices in the U.S., Europe, and Asia.
- Ownership category
- akta.pro rank
SAI MedPartners industry classification
Industry- Product category
- Life Sciences Strategy Consulting
- NAICS
- Other Scientific and Technical Consulting Services (54169), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)
- akta.pro secondary industry
- Healthcare & Life Sciences PR (BPAFADAJ)
Keywords
Where SAI MedPartners is headquartered
LocationHeadquarters
- HQ city
- Reading
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
SAI MedPartners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Strategic Consulting Services: Consulting engagements providing competitive intelligence, market research, forecasting, market access strategy, and path-to-market positioning services to pharmaceutical, biotechnology, and medical device companies.
- Syndicated Reports and Subscriptions: PharmaForce International provides syndicated benchmarking reports covering commercial strategies across therapeutic areas including oncology, immunology, cardiovascular, CNS, and ophthalmology, updated annually.
- Deployment Analyzer Subscriptions: Online tool subscription providing sales force deployment data, updated twice annually per region, with at least five years of historical data. Subscriptions can be tailored by country or therapeutic category.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise consulting services - custom engagements |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
SAI MedPartners product offering
Product offeringCore offering
SAI MedPartners is a global life sciences strategy consultancy that delivers competitive intelligence, market research, forecasting, and market access services to pharmaceutical, biotechnology, and medical device companies. The firm combines deep therapeutic-area expertise with proprietary technology platforms, including an AI-powered synthetic user simulation tool, to support strategic decision-making across the product lifecycle.
Product overview
SAI MedPartners is a global life sciences strategy consultancy offering integrated insights across four core pillars: Competitive Intelligence & Benchmarking, Market Research & Forecasting, Market Access & Pricing, and Path-to-Market & Positioning. The company operates as a unified platform combining consulting services with technology-enabled products. Key offerings include Competitive Intelligence consulting, Fulcrum Research Group (custom market research), IDEA Pharma (path-to-market strategy), and PharmaForce International (syndicated benchmarking). Technology products include Synthetic Users (AI-generated stakeholder simulations), Deployment Analyzer (sales force analytics tool), Syndicated Reports (therapy area benchmarking), and IntelliTraQ (competitive intelligence monitoring). Recent acquisitions of The Dunn Group, PharmaForce International, and Fulcrum Research Group have expanded the portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- Fulcrum Research Group: SAI MedPartners' dedicated healthcare market research division providing custom quantitative and qualitative market research insights
- PharmaForce International
- IDEA Pharma
- Synthetic Users
Products and services
- Competitive Intelligence
- Market Research
- Life Cycle Management
- Forecasting
- Market Access + Pricing
- Path-to-Market + Positioning
- Synthetic Users
- IntelliTraQ
- Deployment Analyzer
- PharmaForce Syndicated Reports
- TheraTraQ
- IDEA Pharma Services
Quantifiable outcome
- 31% of new molecular entities launched since 2021 received strategic support from SAI
- +3 more outcomes
Companies that use SAI MedPartners
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
SAI MedPartners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
SAI MedPartners partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- The Dunn GroupcoreSAI MedPartners acquired The Dunn Group, a competitive intelligence firm based in Totowa, NJ, to enhance its competitive intelligence services. The acquisition strengthens SAI's market position and deepens client relationships in the pharmaceutical, biotechnology, and medical device industries.
- PharmaForce InternationalcoreSAI MedPartners acquired PharmaForce International, a market research and syndicated benchmarking company providing comprehensive commercial competitive benchmarking solutions for pharmaceutical and biotech companies.
- Fulcrum Research GroupcoreNorthlane Capital added Fulcrum Research Group to SAI MedPartners. Fulcrum is a healthcare-focused consulting firm providing custom quantitative and qualitative market research services to pharmaceutical and biotech clients.
- China Policy CenterminorStrategic partnership with China Policy Center for policy interpretation and industry execution assessment, addressing industry players' hot topics and leading to panel discussions exploring executional optimization solutions.
- China CDC and China Association of VaccineminorPartnership for BeSD (Best Immunization Practice) localization to support China's National Immunization Program. Includes design and execution support, optimization of national vaccine strategy with evidence support, and whitepaper publications.
Scale indicators6 records
Expansion highlights6 records
SAI MedPartners competitors and assessment
Company assessmentBroad incumbents
- Charles River Associates (Life Sciences practice): Global consulting firm with a Life Sciences practice providing economic, strategic, and litigation consulting to pharma. Overlaps with SAI in forecasting, market access, HEOR, and pricing strategy but from a broader economic/strategy angle rather than dedicated CI focus.
- IQVIA: Global leader in life sciences technology, analytics, and consulting with deep strategy, CI, market access, real-world evidence, and primary market research offerings. Overlaps with SAI across most of its four pillars but operates at vastly greater scale and a much broader portfolio.
- EVERSANA: End-to-end commercial services provider to life sciences companies, including CI, market research, market access, and HEOR (following its integration of parts of the former Intellisphere/Primary Intelligence practice). Comparable in many SAI service lines though broader in execution/commercialization services.
Direct peers
- ZS Associates: Large global management consulting firm dedicated to healthcare and life sciences, providing strategy, market access, sales/marketing analytics, and CI services to pharma and biotech clients. Closely comparable to SAI in target customer (pharma/biotech leadership), consulting-led GTM, and therapeutic-area depth.
- CBPartners: Boutique life sciences strategy consultancy specializing in market access, pricing, and HEOR for pharma and biotech clients. Direct competitor to SAI's Market Access + Pricing pillar with analogous senior-led, custom-engagement model.
- Trinity Partners: Healthcare-focused strategy consulting firm serving biopharmaceutical, medical device, and diagnostics clients with CI, market access, and commercial strategy engagements. Highly analogous to SAI in service mix, therapeutic depth, and senior-consultant-led delivery model.
- Adelphi Group (Adelphi Research by Design): Healthcare market research and consulting firm serving pharma with custom qualitative and quantitative research, patient research, and CI. Comparable to Fulcrum Research Group sub-brand within SAI in market research methodology and client base.
- Prescient Healthcare Group: Specialized life sciences competitive intelligence and strategy consultancy offering CI, market research, and brand strategy to pharma and biotech. Direct competitor in the SAI core CI business with comparable senior-led engagement model and KOL network depth.
Regional players
- Alligent (now NFP/Life Sciences consulting affiliates): Smaller healthcare-focused competitive intelligence and market research consultancy serving US-based pharma/biotech. Comparable niche, though lacks SAI's Asia footprint and PE-backed scale.
Emerging players
- M3 (MDOutlook / Practice Fusion research adjacencies): Global healthcare data and market research platform with syndicated panels and physician insights. Adjacent rather than direct: comparable in KOL/physician panel data and syndicated benchmarking categories to SAI's Deployment Analyzer and PharmaForce offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
SAI MedPartners social profiles
Digital presenceSAI MedPartners compliance and trust
Trust signalCompliance1 record
SAI MedPartners financial estimates
Financial estimateRevenue estimate
Valuation estimate
SAI MedPartners leadership team
Management profileNumber of profiles
Profiles11 records
SAI MedPartners subsidiaries and ownership
Company hierarchySubsidiaries6 records
SAI MedPartners funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SAI MedPartners M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SAI MedPartners
What does SAI MedPartners do?
SAI MedPartners is a global life sciences strategy consultancy that delivers competitive intelligence, market research, forecasting, and market access services to pharmaceutical, biotechnology, and medical device companies. The firm combines deep therapeutic-area expertise with proprietary technology platforms, including an AI-powered synthetic user simulation tool, to support strategic decision-making across the product lifecycle.
Is SAI MedPartners a public or private company?
SAI MedPartners is a private company. It is classified as private equity controlled and is currently operating.
When was SAI MedPartners founded?
SAI MedPartners was founded in 2011. It employs 101 to 250 people.
Where is SAI MedPartners based?
SAI MedPartners is headquartered in Reading, United States, in the North America region.
How does SAI MedPartners make money?
Three revenue lines are on record. Strategic Consulting Services are the primary driver. The others are syndicated Reports and Subscriptions and deployment Analyzer Subscriptions.
Who are SAI MedPartners's main competitors?
Broad incumbents on record are Charles River Associates (Life Sciences practice), IQVIA and EVERSANA. Direct peers are ZS Associates, CBPartners, Trinity Partners, Adelphi Group (Adelphi Research by Design) and Prescient Healthcare Group. Alligent (now NFP/Life Sciences consulting affiliates) is listed as a regional player. M3 (MDOutlook / Practice Fusion research adjacencies) is listed as an emerging player.
Does SAI MedPartners have an API?
No public API is recorded for SAI MedPartners.
What industry is SAI MedPartners in?
SAI MedPartners's product category is Life Sciences Strategy Consulting. Its primary akta.pro industry code is HLAGAOAG, Medical Affairs, Scientific Communications & HEOR FSP, with a secondary code of BPAFADAJ, Healthcare & Life Sciences PR. Its NAICS code is 54169 and its SIC code is 8000.